ANA GONZALEZ VILLASENOR: Open Payments
NPI 1518573492 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,078 in 105 payments from 20 companies in 2025. Trend: 2023 $1,537 · 2024 $2,007 · 2025 $2,078
Food & beverage: $2,078
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $327 |
| Novo Nordisk Inc | 11 | $228 |
| Amgen Inc. | 14 | $209 |
| AstraZeneca Pharmaceuticals LP | 9 | $192 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $185 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $137 |
| Regeneron Healthcare Solutions, Inc. | 5 | $132 |
| GENZYME CORPORATION | 4 | $113 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $81 |
| Sumitomo Pharma America, Inc. | 3 | $70 |
Products named: DUPIXENT, QULIPTA, XIFAXAN, OTEZLA, CAPLYTA, BREZTRI, Ozempic, Rybelsus.
Industry payments across NY — which companies pay providers there.
